Sutro Biopharma, Inc

ASSOCIATE DIRECTOR, BIOCONJUGATION

Sutro Biopharma, Inc$173K — $196K *
Pharmaceuticals & Biotech
8 - 10 years of experience
Job Overview by Ladders

Qualifications

  • Ph.D. in biochemistry or related field with 8+ years of industry experience.
  • Proven expertise in bioconjugation methods and ADCs.
  • Strong analytical skills with proficiency in HPLC, UV-Vis, DLS, SDS-PAGE, and CE.
  • Knowledge of affinity methods for protein purification and desalting techniques.
  • Familiarity with recombinant protein expression and/or cell-free protein synthesis.

Responsibilities

  • Lead the conjugation team for site-specific bioconjugation of ADCs.
  • Conjugate and characterize ADCs to support early-stage research.
  • Develop analytical strategies to assess conjugation efficiency and properties of ADCs.
  • Collaborate with cross-functional teams to innovate in conjugation chemistry.
  • Advance molecules from early research to development stages.

Benefits

  • Comprehensive health coverage.
  • Retirement plan options.
  • Generous paid time off.
  • Professional development opportunities.
  • Collaborative work environment focused on innovation.
Full Job Description
Description

ASSOCIATE DIRECTOR, BIOCONJUGATION

The successful candidate will serve as a scientific leader in bioconjugation and analytical characterization of conjugates, supporting the discovery and development of next-generation of antibody-drug conjugates (ADCs).

This role will be responsible for driving the development, optimization, and implementation of conjugation technologies and analytical workflows, including mass spectrometry-based characterization of proteins and bioconjugates. The Associate Director will be a member of cross-functional efforts to design, characterize, and advance novel conjugates, and contribute to strategic decisions that impact pipeline and platform development.

Responsibilities:
  • Lead the conjugation team responsible for the development and optimization of site-specific bioconjugation of next-generation ADCs.
  • Conjugate and characterize ADCs to support the early-stage research pipeline.
  • Develop analytical strategies to interrogate conjugation efficiency and biophysical properties of ADCs
  • Coordinate with cross-functional teams to drive innovation in conjugation chemistry and evaluate emerging technologies to enhance Sutro's therapeutic platforms.
  • Collaborate with teams in research and tech ops groups to progress molecules from early leads to early development.


Qualifications:
  • Ph.D. in biochemistry or a related discipline with 8+ years of industry experience
  • Experience developing and troubleshooting bioconjugation methods is required. Experience working with ADCs or antibody fragments is preferred.
  • Proficiency in analytical methods for characterization of proteins and bioconjugates utilizing HPLC (SEC, HIC, RP, and IEX), UV-Vis, DLS, SDS-PAGE, CE, and complementary biophysical techniques.
  • Familiarity with various research-scale affinity methods for protein purification, including desalting, SEC, IMAC, protein A, protein G. Experience with TFF is a plus
  • Experience with recombinant protein expression in E. coli and/or cell-free protein synthesis systems is a plus


Sound exciting? Apply today and join our team!

The anticipated salary range for fully qualified candidates applying for this role at Sutro Biopharma's California based locations will be $173,000 - $196,000 (not including bonus, equity, and benefits). The final salary offered will be dependent on several factors that include and are not limited to relevant previous experience, job responsibilities and duration of experience, the type and length of experience within the industry and education.

About Sutro Biopharma, Inc

Sutro Biopharma is a clinical-stage biotechnology company that develops novel cancer therapies. The company was founded in 2003 and is based in South San Francisco, California. Sutro's proprietary technology platform allows for the rapid design and production of protein therapeutics, which can be used to target specific cancer cells. The company's lead product candidate, STRO-001, is a potential treatment for multiple myeloma and other B-cell malignancies. Sutro has partnerships with several pharmaceutical companies, including Merck and Celgene, to develop and commercialize its products. In 2018, Sutro went public on the NASDAQ stock exchange.
Learn more about Sutro Biopharma, Inc
Size
234 employees
Market Cap
$394.6 million
Industry
Net Income
$12.6 million
Founded
2003
5 Year Trend
+0.7%
Revenue
$45.7 million
NASDAQ

Similar Jobs

More Jobs at Sutro Biopharma, Inc

More Pharmaceuticals & Biotech Jobs

Find similar ASSOCIATE DIRECTOR, BIOCONJUGATION jobs: